Related Experiment Videos
A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group
Insights
Labetalol effectively lowers blood pressure in a diverse patient group, including those unresponsive to other treatments. This antihypertensive medication demonstrated efficacy over one year with manageable side effects.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Hypertension management often requires multiple therapeutic agents.
- Many patients exhibit poor response or intolerance to existing antihypertensive drugs.
- Previous treatments like beta-blockers or diuretics may be insufficient for some individuals.
Purpose of the Study:
- To evaluate the efficacy and tolerability of labetalol in a multicenter clinical trial.
- To assess labetalol's effectiveness in patients with inadequate response to prior therapies.
- To determine the antihypertensive effect of labetalol in previously untreated patients.
Main Methods:
- A multicenter, open-label clinical trial involving 128 patients.
- Patients included those with poor response/side effects to other drugs, inadequate response to diuretics, or who were previously untreated.
- Data collected over a one-year period to assess treatment outcomes.
Main Results:
- Labetalol demonstrated excellent antihypertensive effects, particularly in patients refractory to other medications.
- The drug was effective in 25 patients who required additional agents for blood pressure control.
- A mean daily dose of 707 mg of labetalol was used, with no evidence of tolerance development.
- Side effects led to drug withdrawal in 22% of patients.
Conclusions:
- Labetalol is an effective antihypertensive agent, especially for patients who have not responded well to other treatments.
- While generally well-tolerated, side effects can necessitate dose adjustment or discontinuation.
- Labetalol offers a viable treatment option for a broad spectrum of hypertensive patients.
Abstract:
Labetalol was used in a multicentre open clinical trial in 128 patients in 10 centres. Nearly half had had either poor response to other drugs or side effects with them, while another 25 percent had failed to respond satisfactorily to a diuretic alone and 35 percent were previously untreated. The results at one year showed that labetalol had an excellent antihypertensive effect, often successful in patients who had failed to respond adequately to pure beta-blockers or other drugs and it proved easy to use. Side effects necessitated stopping the drug at less than adequate dosage in some patients who might also have proved resistant to labetalol and other drugs were added to improve blood pressure control in 25 patients who continued labetalol. The mean dose of labetalol was 707 mg/day and there was no evidence of tolerance developing. Side effects were fairly common and led to withdrawal of 28 patients (22 percent).